Ulcer Prophylaxis: Preventing Stomach Ulcers

What is Ulcer Prophylaxis?

Ulcer prophylaxis refers to all preventive strategies aimed at stopping the development of a gastric ulcer (ulcus ventriculi) or a duodenal ulcer (ulcus duodeni). An ulcer forms when the protective lining of the stomach or small intestine is damaged by stomach acid or other harmful factors. Preventive care is especially crucial for patients who face an elevated risk of ulcer formation due to medications, lifestyle, or underlying medical conditions.

Causes and Risk Factors

Understanding the most common causes and risk factors is the foundation of effective ulcer prevention:

• Helicobacter pylori infection: This bacterial infection is one of the most common causes of peptic ulcers worldwide.
• Nonsteroidal anti-inflammatory drugs (NSAIDs): Medications such as ibuprofen, diclofenac, and aspirin inhibit the production of prostaglandins that protect the gastric lining, significantly increasing ulcer risk.
• Corticosteroids: When taken together with NSAIDs, corticosteroids further raise the risk of ulcer formation.
• Physical stress: Serious illness, major surgery, or intensive care can lead to so-called stress ulcers.
• Smoking and alcohol: Both damage the gastric mucosa and stimulate excess acid production.
• Advanced age: Older adults tend to have a thinner, more vulnerable gastric lining.

Who Needs Ulcer Prophylaxis?

Not every person requires medical prophylaxis. The following high-risk groups benefit most from preventive treatment:

• Patients on long-term NSAID therapy (e.g., for arthritis or chronic pain)
• Adults over 65 years of age requiring regular pain medication
• Patients with a previous history of peptic ulcer disease
• Patients taking NSAIDs in combination with corticosteroids or anticoagulants (blood thinners)
• Critically ill patients in intensive care units (stress ulcer prophylaxis)
• Individuals with a confirmed Helicobacter pylori infection

Measures for Ulcer Prophylaxis

Pharmacological Prevention

The most important medical measure is the use of a proton pump inhibitor (PPI) such as omeprazole, pantoprazole, or esomeprazole. PPIs effectively reduce acid secretion in the stomach, thereby protecting the mucosal lining. They are considered the first-line treatment for ulcer prophylaxis in patients taking NSAIDs. Alternatively, H2 blockers (e.g., famotidine) may be used to inhibit acid production, although they are generally considered less effective than PPIs.

Helicobacter Pylori Eradication

When a Helicobacter pylori infection is confirmed, eradication therapy is recommended. This typically involves a combination of two antibiotics and a proton pump inhibitor taken over 7 to 14 days to eliminate the bacterium and reduce the risk of recurrence.

Lifestyle Modifications

In addition to medication, lifestyle changes play an important role in preventing ulcer formation:

• Quitting smoking and reducing alcohol consumption
• Avoiding unnecessary or high-dose NSAID use
• Reducing stress through relaxation techniques or psychological support
• Following a balanced diet and avoiding highly irritating foods
• Taking medications with meals to reduce gastric irritation

Side Effects and Risks of Medical Prophylaxis

Long-term use of proton pump inhibitors is generally well tolerated but may be associated with certain risks. These include an increased risk of magnesium deficiency, vitamin B12 deficiency, gastrointestinal infections (e.g., from Clostridium difficile), and a slightly elevated risk of bone fractures with prolonged use. For this reason, the continued need for PPI therapy should be reviewed regularly by a healthcare provider.

References

1. Deutsche Gesellschaft fur Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS): Guidelines on the Prevention, Diagnosis and Treatment of NSAID-Associated Gastropathy (2022).
2. Malfertheiner P. et al. - Management of Helicobacter pylori infection: the Maastricht VI/Florence Consensus Report. Gut, 2022.
3. Sostres C., Gargallo C. J., Lanas A. - Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Research and Therapy, 2013.